Natarajan Sethuraman - Net Worth and Insider Trading
Natarajan Sethuraman Net Worth
The estimated net worth of Natarajan Sethuraman is at least $3 Million dollars as of 2024-11-05. Natarajan Sethuraman is the President, Research & Develop. of Entrada Therapeutics Inc and owns about 183,216 shares of Entrada Therapeutics Inc (TRDA) stock worth over $3 Million. Details can be seen in Natarajan Sethuraman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Natarajan Sethuraman has not made any transactions after 2024-10-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Natarajan Sethuraman
Natarajan Sethuraman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Natarajan Sethuraman owns 1 companies in total, including Entrada Therapeutics Inc (TRDA) .
Click here to see the complete history of Natarajan Sethuraman’s form 4 insider trades.
Insider Ownership Summary of Natarajan Sethuraman
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
TRDA | Entrada Therapeutics Inc | 2024-10-16 | Chief Scientific Officer |
Natarajan Sethuraman Latest Holdings Summary
Natarajan Sethuraman currently owns a total of 1 stock. Natarajan Sethuraman owns 183,216 shares of Entrada Therapeutics Inc (TRDA) as of October 16, 2024, with a value of $3 Million.
Latest Holdings of Natarajan Sethuraman
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TRDA | Entrada Therapeutics Inc | 2024-10-16 | 183,216 | 17.86 | 3,271,322 |
Holding Weightings of Natarajan Sethuraman
Natarajan Sethuraman Form 4 Trading Tracker
According to the SEC Form 4 filings, Natarajan Sethuraman has made a total of 6 transactions in Entrada Therapeutics Inc (TRDA) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Entrada Therapeutics Inc is the sale of 600 shares on October 16, 2024, which brought Natarajan Sethuraman around $10,800.
Insider Trading History of Natarajan Sethuraman
- 1
Natarajan Sethuraman Trading Performance
Natarajan Sethuraman Ownership Network
Ownership Network List of Natarajan Sethuraman
Ownership Network Relation of Natarajan Sethuraman
Natarajan Sethuraman Owned Company Details
What does Entrada Therapeutics Inc do?
Who are the key executives at Entrada Therapeutics Inc?
Natarajan Sethuraman is the Chief Scientific Officer of Entrada Therapeutics Inc. Other key executives at Entrada Therapeutics Inc include Chief Operating Officer Nathan J Dowden , Chief Financial Officer Kory James Wentworth , and director & President and CEO Dipal Doshi .
Entrada Therapeutics Inc (TRDA) Insider Trades Summary
Over the past 18 months, Natarajan Sethuraman made 5 insider transaction in Entrada Therapeutics Inc (TRDA) with a net sale of 41,938. Other recent insider transactions involving Entrada Therapeutics Inc (TRDA) include a net sale of 12,900 shares made by Dipal Doshi , a net sale of 56,124 shares made by Nathan J Dowden , and a net sale of 49,989 shares made by Kory James Wentworth .
In summary, during the past 3 months, insiders sold 37,284 shares of Entrada Therapeutics Inc (TRDA) in total and bought 0 shares, with a net sale of 37,284 shares. During the past 18 months, 188,553 shares of Entrada Therapeutics Inc (TRDA) were sold and 45,368 shares were bought by its insiders, resulting in a net sale of 143,185 shares.
Entrada Therapeutics Inc (TRDA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Entrada Therapeutics Inc Insider Transactions
Natarajan Sethuraman Mailing Address
Above is the net worth, insider trading, and ownership report for Natarajan Sethuraman. You might contact Natarajan Sethuraman via mailing address: 6 Tide Street, Boston Ma 02210.